/AVBP
AVBP Stock - ArriVent BioPharma, Inc. Common Stock
Healthcare|BiotechnologyNASDAQ
$22.01+3.97%
+$0.84 (+3.97%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.70
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.82
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+99.9%upside
Target: $44.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AVBP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$21.79 – $22.23
TARGET (TP)$44.00
STOP LOSS$20.25
RISK/REWARD1:12.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.95
52W High$29.71
52W Low$15.47
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Income | $-94,308,000 | $-74,590,000 | $-36,906,000 | $-8,696,000 |
| Net Income | $-80,488,000 | $-69,333,000 | $-36,906,000 | $-51,606,000 |
| Net Margin | N/A | N/A | N/A | N/A |
| EPS | $-2.56 | $-2.17 | $-1.10 | $-40.44 |
Company Overview
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
10 Bullish0 Neutral/Bearish
Price Targets
$36
Average Target
↑ 61.3% Upside
Now
$25
Low
$36
Average
$45
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 10th 2025 | BTIG Research | Initiation | Buy | $45 |
| November 25th 2025 | Truist | Initiation | Buy | $43 |
| July 10th 2025 | Goldman | Resumed | Buy | $33 |
| March 20th 2025 | B. Riley Securities | Initiation | Buy | $37 |
| March 10th 2025 | Guggenheim | Initiation | Buy | $45 |
| July 22nd 2024 | Oppenheimer | Initiation | Outperform | $35 |
| April 30th 2024 | H.C. Wainwright | Initiation | Buy | $25 |
| February 20th 2024 | Jefferies | Initiation | Buy | $35 |
| February 20th 2024 | Goldman | Initiation | Buy | $27 |
| February 20th 2024 | Citigroup | Initiation | Buy | $30 |
Earnings History & Surprises
AVBPBeat Rate
50%
Last 8 quarters
Avg Surprise
-15.1%
EPS vs Estimate
Beats / Misses
4/3
1 met exactly
Latest EPS
$-0.83
Q4 2025
EPS Surprise History
Q1 24
+36.4%
$-0.70vs$-1.10
Q2 24
+16.7%
$-0.70vs$-0.84
Q3 24
0.0%
$-0.65vs$-0.65
Q4 24
+25.6%
$-0.61vs$-0.82
Q1 25
+23.1%
$-0.60vs$-0.78
Q2 25
-187.9%
$-1.90vs$-0.66
Q3 25
-28.6%
$-0.90vs$-0.70
Q4 25
-6.4%
$-0.83vs$-0.78
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $-0.87 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.78 | $-0.83 | -6.4% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.70 | $-0.90 | -28.6% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.66 | $-1.90 | -187.9% | ✗ MISS |
Q1 2025 | Mar 3, 2025 | $-0.78 | $-0.60 | +23.1% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.82 | $-0.61 | +25.6% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.65 | $-0.65 | 0.0% | = MET |
Q2 2024 | May 8, 2024 | $-0.84 | $-0.70 | +16.7% | ✓ BEAT |
Q1 2024 | Jan 26, 2024 | $-1.10 | $-0.70 | +36.4% | ✓ BEAT |
Q3 2023 | Sep 30, 2023 | — | $-0.43 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.64 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.36 | — | — |
Q4 2022 | Dec 30, 2022 | — | $-0.31 | — | — |
Q3 2022 | Sep 29, 2022 | — | $-0.35 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-5.76 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-5.76 | — | — |
Latest News
BTIG Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $45
📈 PositiveBenzinga•Dec 10, 2025, 12:34 PM
Truist Securities Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $43
📈 PositiveBenzinga•Nov 25, 2025, 06:02 PM•Also:
Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $31
➖ NeutralBenzinga•Nov 11, 2025, 08:35 PM•Also:
ArriVent BioPharma Q3 EPS $(0.83) Misses $(0.81) Estimate
📉 NegativeBenzinga•Nov 10, 2025, 01:05 PM
ArriVent BioPharma Presents Final Proof-Of-Concept Data From Randomized Global Phase 1b FURTHER Trial For First-Line Firmonertinib Monotherapy In Patients With NSCLC Harboring EGFR PACC Mutations At IASCLC 2025
📈 PositiveBenzinga•Sep 9, 2025, 12:07 PM
ArriVent Posts Wider Loss in Fiscal Q2
📉 NegativeThe Motley Fool•Aug 11, 2025, 12:11 PM
ArriVent announces $75M public offering
➖ NeutralSeeking Alpha•Jul 1, 2025, 08:13 PM
Frequently Asked Questions about AVBP
What is AVBP's current stock price?
ArriVent BioPharma, Inc. Common Stock (AVBP) is currently trading at $22.01 per share. The stock has moved +3.97% today.
What is the analyst price target for AVBP?
The average analyst price target for AVBP is $44.00, based on 1 analyst.
What sector is ArriVent BioPharma, Inc. Common Stock in?
ArriVent BioPharma, Inc. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is AVBP's market cap?
ArriVent BioPharma, Inc. Common Stock has a market capitalization of $0.91 billion, making it a small-cap company.
Does AVBP pay dividends?
No, ArriVent BioPharma, Inc. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARVN
Arvinas, Inc.
$11.68
Mkt Cap: $0.8B
ATXS
Astria Therapeutics, Inc.
$12.83
Mkt Cap: $0.7B
DAWN
Day One Biopharmaceuticals, Inc.
$9.24
Mkt Cap: $0.9B
DNA
Ginkgo Bioworks Holdings, Inc.
$8.10
Mkt Cap: $0.4B
ERAS
Erasca, Inc.
$3.45
Mkt Cap: $1.0B
IOVA
Iovance Biotherapeutics, Inc.
$2.48
Mkt Cap: $0.8B
MBX
MBX Biosciences, Inc. Common Stock
$30.42
Mkt Cap: $1.0B
MGTX
MeiraGTx Holdings plc
$8.03
Mkt Cap: $0.6B
REPL
Replimune Group, Inc.
$9.88
Mkt Cap: $0.8B
VALN
Valneva SE
$8.07
Mkt Cap: $0.7B
Explore stocks similar to AVBP for comparison